Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2237-2240

  Bhagunde, Pratik ^a   Chang, Kai Tai ^a   Hirsch, Elizabeth B ^a   Ledesma, Kimberly R ^a   Nikolaou, Michael ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; IMIPENEM; MK 7655; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG EFFICACY; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AZABICYCLO COMPOUNDS; BETA-LACTAMASES; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MEMBRANES, ARTIFICIAL; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PRACTICE GUIDELINES AS TOPIC;

EID: 84860188286     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06113-11     Document Type: Article

References (13)

1. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
2. Bhagunde P, Chang KT, Hirsch EB, Nikolaou M, Tam VH. 2011. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr A-1686.
3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201.
5. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. 2010. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 54:109-115.
6. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607. (Pubitemid 40691835)
7. Norrby SR, Bjornegard B, Ferber F, Jones KH. 1983. Pharmacokinetics of imipenem in healthy volunteers. J. Antimicrob. Chemother. 12(Suppl D):109-124. (Pubitemid 14217860)
8. Painter RE, Young K. 2007. Carbapenem-hydrolyzing beta-lactamases KPC-2 and KPC-3 in Klebsiella pneumoniae isolates from Florida, abstr A-016. Abstr. 107th Gen. Meet. Am. Soc. Microbiol., Toronto, Ontario, Canada.
9. Talbot GH, et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668. (Pubitemid 43271379)
10. Tam VH, et al. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428. (Pubitemid 41023120)
11. Tam VH, Nikolaou M. 2011. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput. Biol. 7:e1001043.
12. Tam VH, et al. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927. (Pubitemid 41778901)
13. Tam VH, et al. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3624-3630. (Pubitemid 41233009)